Verseau Therapeutics Competitors and Similar CompaniesClear all
Verseau Therapeutics's competitors and similar companies include Boundless Bio, ADC Therapeutics, Curis and FoRx Therapeutics.
 Verseau Therapeutics Verseau Therapeutics is a company that develops macrophage checkpoint modulators designed to benefit patients with cancer, immune and inflammatory diseases. |  Boundless Bio Boundless Bio is a developer of novel cancer therapeutics intended to understand and treat intractable cancers. |  ADC Therapeutics ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers. |  Curis Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers. |  FoRx Therapeutics FoRx Therapeutics is a company that develops cancer drugs intended to focus on novel DNA Replication Stress pathways activated in cancer. | |
Founding Date | Founding Date 2017 | Founding Date 2019 | Founding Date 2010 | Founding Date 2000 | Founding Date 2019 |
Type | Type Private | Type Public | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Bedford, US HQ | Locations San Diego, US HQ | Locations Epalinges, CH HQ London, GB New Providence, US | Locations Lexington, US HQ Lexington, US | Locations Basel, CH HQ |
Employees | Employees 6 | Employees 2856% decrease | Employees 1162% increase | Employees 3144% decrease | Employees 343% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 295.9 m | Valuation ($) 29.4 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $81.4m (FY, 2025) | Revenue (est.) $9.4m (FY, 2025) | Revenue (est.) N/A |
Net income | Net income N/A | Net income ($58.2m) (FY, 2025) | Net income ($142.6m) (FY, 2025) | Net income ($7.6m) (FY, 2025) | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round $ 50m (over 6 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 10.8m (about 6 years ago) |
Total funding raised | Total funding raised $ 50m | Total funding raised $ 46.4m | Total funding raised $ 526m | Total funding raised N/A | Total funding raised $ 10.8m |
For sources of this data, please see the company profile
View Company Profiles
Boundless Bio
HQ
San Diego, US
Employees
28
Boundless Bio is a developer of novel cancer therapeutics intended to understand and treat intractable cancers.
View companyADC Therapeutics
HQ
Epalinges, CH
Employees
116↑ 2% increase
ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers.
View companyCuris
HQ
Lexington, US
Employees
31↓ 44% decrease
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers.
View companyFoRx Therapeutics
HQ
Basel, CH
Employees
34↑ 3% increase
FoRx Therapeutics is a company that develops cancer drugs intended to focus on novel DNA Replication Stress pathways activated in cancer.
View company